Cortecs International Ltd. announced Tuesday that it is seekingregulatory approval to start combined Phase II/III clinicaltrials of its anti-cancer targeting system.
The London company's decision rests on the data from initialtests of its Oncholab system, which incorporates anti-cancerdrugs into low-density lipoproteins (LDLs), that the companypresented recently at the Sixth International Symposium onRecent Advances in Drug Delivery Systems held in Salt LakeCity.
The data stem from studies in animals as well as in humans. Inone experiment, mice with experimental leukemia thatreceived LDL vincristine survived beyond the end of the study(mean greater than 60 days), while animals receiving the drugalone survived only 27 days. The untreated controls died after15 days.
In a clinical study conducted in Poland on humans sufferingfrom ovarian or endometrial cancer, patients who received LDLvincristine showed no serious neurological side effects; fourpatients even showed unexpected therapeutic responses.
By incorporating anti-cancer drugs into LDL particles, Cortecsintends to target those drugs to tumor cells, which overexpressLDL receptors. This should internalize the drug within thecancer cell, thus increasing its effectiveness and reducingunwanted side effects.
The Oncholab system was invented by scientists at KarolinskaInstitute in Sweden. Cortecs said it will conduct its proposedPhase II/III trials in both Sweden and Poland.
-- Jennifer Van Brunt Senior Editor
(c) 1997 American Health Consultants. All rights reserved.